13D Filing: Glaxosmithkline Plc and Htg Molecular Diagnostics Inc (NASDAQ:HTGM)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities
Exchange Act of 1934
(Amendment No. 1)*

HTG MOLECULAR
DIAGNOSTICS, INC.

(Name of Issuer)

Common Stock,
Par Value $0.001

(Title of Class of Securities)

40434H 10
4

(CUSIP Number)

Victoria A. Whyte

GlaxoSmithKline
plc

980 Great West Road

Brentford, Middlesex TW8 9GS

England

Telephone: +44 (0)208 047 5000

(Name, Address and Telephone Number
of Person
Authorized to Receive Notices and Communications)

March 27,
2017

(Date of Event which Requires Filing
of this Statement)

If the filing person has previously filed a
statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because
of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format
shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties
to whom copies are to be sent.

^* The remainder of this cover page
shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of
this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934
(“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act.